Lyell Immunopharma gets FDA RMAT status for lymphoma treatment
Source: SeekingAlpha
2025-04-15 11:02:41 ET
More on Lyell Immunopharma
- Seeking Alpha’s Quant Rating on Lyell Immunopharma
- Historical earnings data for Lyell Immunopharma
- Financial information for Lyell Immunopharma
Read the full article on Seeking Alpha
For further details see:
Lyell Immunopharma gets FDA RMAT status for lymphoma treatment
Lyell Immunopharma Inc.
NASDAQ: LYEL
LYEL Trading
-8.66% G/L:
$22.26 Last:
56,636 Volume:
$24.78 Open:
LYEL Latest News
March 12, 2026 04:05:00 pm
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
March 09, 2026 08:00:00 am
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
February 23, 2026 08:00:00 am
Lyell Immunopharma Announces Participation in March Investor Conferences
LYEL Stock Data
$503,932,654
12,184,349
0.5%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
